To address this gap, this study developed and validated a novel SREBP2-integrated nomogram for improved risk stratification in 206 HCC patients undergoing LT (2015-2022), randomly split into development (n = 144) and validation (n = 62) cohorts. This evidence concerns the gene SREBF2 and hepatocellular carcinoma.